These results demonstrated that FOXP2 might inhibit the EMT of breast cancer cells by directly stimulating the transcription of epithelial-driven gene PHF2, contrary to the general notion of FOXP2 mainly acting as a transcriptional repressor. The gene discussed is PHF2; the disease is breast carcinoma.